EOLSEvolus, Inc.
$7.79+24% 1Y
$7.79
$3.9452 weeks$9.30
The financials
Evolus, Inc. by the numbers
Evolus, Inc. (EOLS) reported revenue of $84M in Q2 2026 (quarter ended Jun 30, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 68% and net loss of $8.1M. For the full year FY2025, revenue was $297M (+12% year on year) and net income −$52M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $84M | $69M | +21% |
| Gross profit | $57M | $45M | +26% |
| Operating income | −$4.5M | −$10M | n/a |
| Net income | −$8.1M | −$17M | n/a |
| Diluted EPS | −$0.12 | −$0.27 | n/a |
Drug Manufacturers, Specialty & Generic
Ranks #35 of 41 by RyuScore